Abstract

Anesthesiology's Journal CME is open to all readers. Members of the American Society of Anesthesiologists (ASA) enjoy a preferred rate for their subscription. However, Journal CME is not limited to ASA members or Journal subscribers. To take part in Journal CME, complete the following steps:The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The American Society of Anesthesiologists designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.Purpose: The focus of Anesthesiology Journal CME is to educate readers on current developments in the science and clinical practice of anesthesiology.Target Audience: Anesthesiology Journal CME is designed for physicians involved with anesthesiology education, clinical practice, and research.Editor-in-Chief: James C. Eisenach, M.D., has no relevant financial relationships to disclose.CME Editors: Leslie C. Jameson, M.D., and Richard P. Dutton, M.D., M.B.A., have no relevant financial relationships to disclose.ASA Staff: Employees involved in planning have no relevant financial relationships to disclose.All tests and requests for credit must be submitted through the Anesthesiology CME website at www.asahq.org/journal-cme. Participants should claim credit in 15-minute increments, for a maximum of 1 AMA PRA Category 1 Credit(s) ™ per journal article.Two payment options are available:ASA Member Non-memberAnnual Fee $60 $120Per Issue $10 $20Payment may be made using Visa or MasterCard.Please direct any questions about Journal CME to:Joyce CanselorEducation Coordinator, CME(847) 268-9185j.canselor@asahq.orgRead the article by Dahan et al . entitled “Incidence, reversal, and prevention of opioid-induced respiratory depression” on page 226 of this issue.After completing this activity, the learner will understand the effects of opioid agonists on the central nervous system, be able to recognize and treat respiratory depression caused by opioid agonists, and understand the risks and benefits of naloxone administration.Authors: Albert Dahan, M.D., Ph.D., returned a disclosure form indicating that he received funded research from Gruenenthal GmbH Aachen, Mundipharma Cambridge UK, Eurocept NL, and Abbott Netherlands, and other material support from Aspect MS Int. Leon Aarts, M.D., Ph.D., and Terry W. Smith, Ph.D., returned disclosure forms indicating that they have no financial interest in or affiliation with any commercial supporter or providers of any commercial services discussed in this educational material.Registration and submission of answers must be completed by January 31, 2013.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call